跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04079933
NCT04079933已完成不适用

A Randomized, Controlled, Parallel Group Clinical Study of Cigarette Smokers Using an Innovative Oral Tobacco-derived Nicotine Product to Determine Impact on Cigarette Consumption and Biomarkers of Exposure

Altria Client Services LLC6 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2013年8月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
154
试验地点
6
主要终点
Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively.

详细描述

This was a randomized, controlled, open-label, parallel group, multicenter, 9-week study to determine changes in BOE in adult smokers allowed ad libitum use of an OTDN product relative to adult smokers who were not allowed to use an OTDN product. This study was conducted in adult smokers who were considered to be in overall good health. Subjects were randomized to Test (allowed OTDN use) or Control (not allowed OTDN use) groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
21 Years 至 65 Years（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Subject must:
  • •sign an Institutional Review Board (IRB)-approved ICF for the study.
  • •be between the ages of 21 and 65 years, inclusive, at the time of Screening.
  • •have consumed a minimum of 10 manufactured CPD daily during the last 6 months (entire 6 month period must have occurred after subject turned 21 years of age).
  • •indicate that he/she smokes cigarettes "every day" at Screening and on Day 1
  • •be able to fully comprehend the English language.
  • •have an active phone number and must have daily access to a touchtone phone between 1600 and 1900 hours.
  • •be interested in alternative tobacco products to cigarettes at Screening.
  • •indicate that they "definitely would buy" or "probably would buy" on the VBM-FG2 Potential Purchase Interest Questionnaire.
  • •be in generally good health.
  • •if female, have a negative urine dipstick pregnancy test.
  • •if female heterosexually active and of childbearing potential (i.e., not surgically sterile or two years naturally postmenopausal), agree to use a medically accepted method of contraception from Screening through the End of Study.
  • •have clinical laboratory tests within the appropriate reference range or which are clinically acceptable to the Investigator.
  • •have a negative ethanol, amphetamines, opiates, cannabinoids, and cocaine urine drug screen.
  • •test negative for human immunodeficiency (HIV), hepatitis B (hepatitis B surface antigen [HBsAg]), and Hepatitis C (anti-hepatitis C virus antibody [anti-HCV]).
  • •be willing and able to comply with the requirements of the study.

排除标准

  • •Subject must not:
  • •be pregnant, nursing, or planning to become pregnant during the study period.
  • •indicate that he/she intends to quit smoking within the next 30 days (at Screening or on Day 1).
  • •have uncontrolled hypertension, history of coronary heart disease or other significant heart conditions, and/or other significant medical conditions that might interfere with study procedures.
  • •have used prescription anti-diabetic medication and/or insulin therapy within 12 months of Day
  • •have a history of drug or alcohol abuse within the 24 months prior to Screening.
  • •have participated in a clinical study for an investigational drug, device, or biologic within 30 days prior to enrollment (Day 1).
  • •be a current user of nicotine replacement therapy (indicate every day or some days on Subject Screener/Tobacco History Questionnaire).
  • •be a current or former employee of the tobacco industry or a first-degree relative (e.g., parent, sibling, child) of a current or former employee of the tobacco industry.
  • •have been involved in the development of the study design/conduct or be a first-degree relative (e.g., parent, sibling, child) of someone involved in the development of the study design/conduct.
  • •be a current employee or personnel involved with the study at the study site.
  • •be currently participating in the study at a different study site (i.e., each subject can only be in the study population once).

研究组 & 干预措施

Group 1: Continue Smoking

No Intervention

Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks

Group 2: OTDN

Experimental

Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint [VBM-FG2]) also under ad libitum conditions

干预措施: Oral tobacco-derived nicotine product (OTDN) (Other)

结局指标

主要结局

Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population)

时间窗: Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1)

Summary statistics of percent change from baseline for urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol \[NNAL\] (%) in each study visit are presented. Baseline taken from Visit 3 (Day 8±1) value. Visit 4 = Day 15±1 Visit 5 = Day 22±1 Visit 6 = Day 29±1 Visit 7/End of Study = Day 36±1 Mean percent change from baseline is the mean of all individual subjects' percent change from baseline values. Each percent change from baseline was calculated by subtracting the individual subject's baseline value from the value at the desired timepoint and then dividing this calculated value by the individual subject's baseline value and multiplying by 100. These individual subjects' percent changes from baseline values were used to calculate the mean percent change from baseline using a Statistical Analysis System (SAS®) procedure.

次要结局

  • Summary Statistics of Change From Baseline for Urinary Total NNAL (ng/g Creatinine) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline for Nicotine Equivalents (mg / g Creatinine) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Percent Change From Baseline for Nicotine Equivalents (%) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline for S-phenyl Mercapturic Acid (S-PMA) (ng/g Creatinine) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Percent Change From Baseline for S-PMA (%) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Percent Change From Baseline for Carboxyhemoglobin (%) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline for Exhaled Carbon Monoxide (Ppm) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Percent Change From Baseline for Exhaled Carbon Monoxide (%) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline in Cigarettes Smoked Per Day (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Percent Change From Baseline for Cigarettes Smoked Per Day (CPD) (Per-Protocol Population)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Change From Baseline for Total Score of Fagerstrom Test for Cigarette Dependence (Per-Protocol Population)(Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quit Attempts (Per-Protocol)(Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Count of Subjects in Subgroups Based on Change From Baseline to End of Study on Change in Quitting Intentions (Per-Protocol)(Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Difference in Means of Urinary Total NNAL Exposure Between Day 1 and Day 8 (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Difference in Means of Nicotine Equivalents Exposure Between Day 1 and Day 8 (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Difference in Means of S-PMA Exposure Between Day 1 and Day 8 (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Difference in Means of Carboxyhemoglobin (COHb) Exposure Between Day 1 and Day 8 (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Difference in Means of Carbon Monoxide (CO) Exposure Between Day 1 and Day 8 (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Difference in Cigarettes Per Day Between the Once Weekly Recall at Day 8 (From Questionnaire) and the Average Daily Tracking Days 2 Through 8 (From IVRS) (Per-Protocol)(Daily during Baseline Period (Day 1 to Day 8))
  • Frequency and Percentage of Subjects With Change From Baseline in Urinary Total NNAL (ng / g Creatinine)(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7))
  • Frequency and Percentage of Subjects With Change From Baseline in Cigarette Consumption(Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7))
  • Frequency and Percentage of Subjects With Change From Baseline in Quitting Intentions(Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))
  • Summary Statistics of Cigarettes Smoked Per Day on Visits 2 (Day 1) and 3 (Day 8)(Day 1 (Visit 2) and Day 8 (Visit 3))
  • Summary Statistics of Carboxyhemoglobin by Study Group and Cigarette Consumption Categories Over Visits(Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7))
  • Summary Statistics of Exhaled Carbon Monoxide by Study Group and Cigarette Consumption Categories Over Visits(Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7))
  • Summary Statistics of S-PMA by Study Group and Cigarette Consumption Categories Over Visits(Day 1 (Visit 2), Day 8 (Visit 3), Day 15 (Visit 4), Day 22 (Visit 5), Day 29 (Visit 6) and Day 36 (Visit 7))
  • Descriptive Statistics for Cigarettes Smoked Per Day (CPD) (Recall Data) in Day 1 and 8 (Respectively) by Study Group and Cigarette Consumption Categories(Day 1 (Visit 2) and Day 8 (Visit 3))
  • Summary Statistics of Cigarettes Smoked Per Day (IVRS Data) by Study Group and Cigarette Consumption Categories on Days 1 Through 8(Daily during Baseline Period (Day 1 to Day 8))
  • Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group(Day 8 (Visit 3) and End of Study (Day 36±1))
  • Median Change From Baseline to End of Study for Urinary Total NNAL by Study Group and Cigarette Consumption Categories(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Percent Change From Baseline to End of Study Summary Statistics of Urinary Total NNAL (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (mg/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Percent Change From Baseline to End of Study Summary Statistics of Nicotine Equivalents (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Change From Baseline to End of Study Summary Statistics of S-PMA (ng/g Creatinine) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Percent Change From Baseline to End of Study Summary Statistics of S-PMA (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Percent Change From Baseline to End of Study Summary Statistics of Carboxyhemoglobin (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (Ppm) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Percent Change From Baseline to End of Study Summary Statistics of Exhaled Carbon Monoxide (%) by Study Group and Cigarette Consumption Categories Over Visits(Day 8 (Visit 3) and Day 36 (Visit 7/End of Study))
  • Characterization of Subgroups Based on Change From Baseline in Total NNAL(Day 36 (Visit 7/End of Study) relative to the start of the baseline period (Visit 2/Day 1))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

已完成
不适用
Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely Switch to E-vapor ProductsTobacco Use
NCT04800211Altria Client Services LLC450
已完成
不适用
Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDSElectronic Cigarette UseCigarette Use, ElectronicTobacco UseTobacco Smoking
NCT04107779Juul Labs, Inc.279
已完成
不适用
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 WeeksSmoking
NCT02396381Philip Morris Products S.A.1,039
已完成
不适用
Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine GumSmoking
NCT02323438R.J. Reynolds Vapor Company153
已完成
不适用
Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.Smoking
NCT02503254Philip Morris Products S.A.85